Last reviewed · How we verify
NCT06915194
SMART Pilot Trial of Glycemic Screening Outreach
NA trial testing Text message in Overweight (BMI > 25) in 105 participants. Enrolling by invitation.
8 October 2025
Quick facts
| Lead sponsor | University of California, Los Angeles |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 105 |
| Start date | 8 July 2025 |
| Primary completion | 8 October 2025 |
| Estimated completion | 8 November 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Text message — full drug profile →
- Patient portal message
- Mailed letter
Conditions studied
- Overweight (BMI > 25) — all drugs for Overweight (BMI > 25) →
- Obesity — all drugs for Obesity →
Sponsor
University of California, Los Angeles
Who can join
Adults 35 to 70, any sex, with Overweight (BMI > 25) or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Approximately 130 million Americans have prediabetes or type 2 diabetes (T2D) but remain unscreened and/or unaware of their diagnosis. While prediabetes/T2D screening, also known as glycemic screening, is endorsed in national guidelines, there is almost no research on how to increase screening rates, or evaluations of interventions testing the effectiveness of screening promotion strategies. The American Medical Association has published prediabetes quality measures that apply to UCLA Health as well as all other health systems, specifically tracking the percentage of adult patients with risk factors for T2D due for glycemic screening for whom the screening process was initiated. However, there is no current systemic effort underway at UCLA, or most other health systems, to encourage glycemic screening. We are proposing a pilot trial of the first SMART (Sequential Multiple Assignment Randomized Trial) for glycemic screening. Our SMART experiment will provide preliminary feasibility and acceptability data for a larger, multisite trial that will provide vital guidance to optimize screening approaches for a growing number of screening-eligible patients so that they may seek earlier detection, treatment, and/or access to lifestyle programs and interventions for T2D or prediabetes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06915194
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Text message
Trials testing the same drug.
- NCT06932718 — Smoking Cessation Programme in Workplaces in Hong Kong (Phase ⅤII) · NA · recruiting
- NCT06246812 — Text Message and Competition-Based Interventions Among University Students · NA · completed
- NCT05037201 — Text Message Nudges for COVID-19 Vaccination · NA · completed
- NCT04772521 — Smoking Cessation Programme in Workplaces in Hong Kong (Phase Ⅴ) · NA · unknown
- NCT05778240 — Adherence to Palivizumab Prophylaxis · NA · completed
Other recruiting trials for Overweight (BMI > 25)
Currently open trials in the same condition.
- NCT07196852 — Redox Status and Exercise Training-induced Adaptations · NA · recruiting
- NCT07340125 — Pistachio Snacking and Metabolic Flexibility · NA · recruiting
- NCT07073781 — Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regul · NA · recruiting
- NCT07076563 — Ice Cream Enriched With Cimarrón Bean Extrudate and Cardiovascular Risk in Adults · NA · active not recruiting
- NCT07255300 — Follow up Study of Varapodio Trial: Effect of Longevity and Fasting Mimicking Diet on Risk Factors Age Correlated and Bi · NA · recruiting
Other University of California, Los Angeles trials
Trials by the same sponsor.
- NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
- NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
- NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
- NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
- NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06915194 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
- Last refreshed: 17 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06915194.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing